Clinical Trial

CRISAL Study:Cancer Risk In Secreting Adrenal Lesions

Study acronym: CRISAL
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2024 (before its estimated September 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-19.
Trial Details
NCT Number NCT06520111
Lead Sponsor University of Roma La Sapienza
Conditions Adrenal Tumor, Adrenal Incidentaloma, Surgery
Enrollment 300 participants
Start Date 2024-08-27
Primary Completion 2024-09-30 (estimated)
Study Completion 2024-11-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-30